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Introduction
Venous thromboembolism (VTE), comprising deep vein
thrombosis (DVT) and pulmonary embolism (PE), has an
annual incidence of approximately 100 to 200 per 100,000
patient-years and is associated with considerable morbidity
and mortality.1,2 VTE can be categorized broadly as either
provoked or unprovoked.3–5 Traditionally, VTE is considered
provoked if it occurs in conjunctionwithmajor transient risk
factors, such as surgery or trauma; VTE can also be provoked
by major persistent risk factors such as cancer. In contrast, if
VTE occurs in the absence of such risk factors, it is considered
unprovoked. The distinction between provoked and unpro-
voked VTE is important when considering the duration of
anticoagulation treatment. In all cases, anticoagulation treat-
ment is recommended for at least 3 months,3,6,7 at which
point the decision to extend therapy is based on the balance
between the risk of recurrent VTE if anticoagulation therapy
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Abstract Traditionally, venous thromboembolism (VTE) resulting from major transient risk
factors (e.g., surgery or trauma) or a major persistent risk factor such as cancer, has
been deﬁned as being provoked, whereas unprovoked VTE encompasses events
without an identiﬁable cause. These categorizations inﬂuence anticoagulant treatment
duration; unlike VTE provoked by major transient risk factors, extended anticoagula-
tion beyond 3months is advised for patients with cancer or unprovoked VTE due to risk
persistence after treatment cessation. However, some patients with VTE provoked by
minor transient or minor persistent risk factors may also be candidates for extended
anticoagulation therapy due to the continuing risk of recurrence. In patients who
require extended therapy, vitamin K antagonists (VKAs) are effective but are associated
with an increased risk of bleeding and various treatment burdens (e.g., anticoagulation
monitoring and dose adjustment). Evaluations of extended VTE treatment with the
less-burdensome direct oral anticoagulants such as apixaban, dabigatran, edoxaban,
and rivaroxaban show that they are at least as safe and effective as VKAs in a broad
range of patients. In addition, apixaban and rivaroxaban offer more than one dosing
option, allowing tailoring of treatment to the patient’s speciﬁc risk factor proﬁle.
Analysis of more granular deﬁnitions for risk factor groupings has also yielded vital
information on the most appropriate strategies for the treatment of patients with
speciﬁc risk factors, highlighting that extended anticoagulation treatment may beneﬁt
those with minor transient and persistent environmental and nonenvironmental risk
factors who commonly receive shorter-duration therapy.
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is stopped and the risk of bleeding if it is continued. Patient
preferences also need to be considered, as well as cost and
reimbursement for extended anticoagulation therapy.
A 3-month course of anticoagulation therapy is usually
adequate for VTE provoked by major transient risk factors,
provided that the risk factors have resolved. If anticoagula-
tion therapy is stopped after 3 months in such patients, the
risk of recurrence is approximately 1% at 1 year and 3% at
5 years.4 In contrast, when anticoagulation is stopped in
patients with unprovoked VTE, the cumulative risk of recur-
rence is approximately 10% at 1 year and 30% at 5 years. In
patients with unprovoked proximal DVT or PE, the risk of
recurrence in the ﬁrst 6 months after stopping therapy has
been demonstrated to be signiﬁcantly higher in patientswho
received anticoagulation for 3 months as opposed to
6 months or longer.4,8 Consequently, extended anticoagula-
tion therapy is often prescribed for such patients. Extended
anticoagulation therapy is deﬁned by the American College
of Chest Physicians as continued treatment with no speciﬁed
stop date, but with periodic evaluation on at least a yearly
basis to reassess the need for continued therapy and to
evaluate the risk of bleeding.6 Patients with VTE provoked
by major persistent risk factors such as active cancer are at
the highest risk of recurrence.4 In those with metastatic
disease, the risk of recurrence if anticoagulation therapy is
stopped is at least 15% at 1 year; long-term prognosis is so
poor that recurrence rates at 5 years cannot be determined.6
Therefore, extended anticoagulation is also prescribed for
most patients with VTE provoked by active cancer.6
Accumulating evidence suggests that the traditional dis-
tinction between provoked and unprovoked VTE is overly
simplistic because it fails to account for VTE provoked by
minor transient risk factors, such as travel, or by minor
persistent nonenvironmental risk factors, such as inﬂamma-
tory bowel disease (IBD), congestive heart failure (CHF), high
body mass index (BMI), thrombophilia, renal impairment,
limb paralysis or paresis, prior VTE, or family history of
VTE.9–11This isproblematic because the riskofVTE recurrence
if anticoagulation is stopped after 3 to 6 months in such
patients is higher than in patientswithVTE triggered bymajor
transient risk factors and potentially not dissimilar to the risk
associatedwith unprovokedVTE.9,11A list of provoking factors
within each risk factor category is shown in ►Table 1.
The purpose of this review is to provide guidance on
which patients with VTE should be considered for extended
anticoagulation therapy, taking into account new evidence
regarding the less clearly elucidated minor transient or
persistent risk factors and the optimal anticoagulant drug
and dosing selection for such patients.
Anticoagulants for the Extended Treatment
of Venous Thromboembolism
Vitamin K Antagonists
Several studies have compared the efﬁcacy and safety of
vitamin K antagonists (VKAs) with shorter treatment dura-
tions versus longer treatment durations in patients with
provoked and unprovoked VTE. The shorter treatment dura-
tions in these trials ranged from 4 weeks to 6 months,
whereas longer treatment durations ranged from 12 weeks
to 48 months.12,13 Overall, these trials revealed that longer
treatment with VKAs reduced the risk of recurrent VTE by
80%, but was associated with a threefold increase in major
bleeding.12,13 Therefore, lower-intensity VKA treatment reg-
imens were evaluated in an attempt to improve the beneﬁt–
risk proﬁle of extended VTE therapy.
Lowered-Intensity Vitamin K Antagonist Regimens
A study comparing low-intensity warfarin therapy (target
international normalized ratio [INR] 1.5–2.0) with placebo
for extended therapy in patients with unprovoked VTE (who
had received full-dose anticoagulation therapy for amedian of
6.5months before randomization)was stopped early after 508
patientswere enrolled. Comparedwith placebo, low-intensity
warfarin signiﬁcantlydecreased the rateof recurrentVTE from
Table 1 VTE provoking factors by category in the EINSTEIN
EXT/EINSTEIN CHOICE baseline risk factor pooled analysis9
Risk factor and category
Minor transient
Immobilization (due to a medical disorder, excluding
BMI>30 kg/m2, and major surgery)
Lower limb trauma with transient impairment of mobility
(including orthopedic surgery/arthroscopy, but excluding
hip or knee replacement)
Pregnancy, puerperium (including cesarean section)
Air travel>8 hours
Use of estrogen therapy (hormonal contraceptive or
postmenopausal therapy)
Minor persistent
BMI>30 kg/m2
CHF
CrCl<50 mL/min
Family history of VTE or known thrombophiliaa
IBD (diagnosed in accordance with the European Crohn’s
and Colitis Organisation guidelines)
Lower extremity paralysis or paresis
Major transient
Major surgery or trauma (major surgery or major trauma,
excluding leg injuries)
Cesarean section
Major persistent
Active cancer at baseline (diagnosis or treatment<6months
or recurrent or metastatic cancer [excluding basal cell or
squamous cell skin cancer])
Abbreviations: BMI, body mass index; CHF, congestive heart failure;
CrCl, creatinine clearance; IBD, inﬂammatory bowel disease; VTE,
venous thromboembolism.
aIncluding deﬁciency of antithrombin, protein C, protein S, factor V
Leiden or prothrombin gene mutation, and antiphospholipid syn-
drome; however, due to differences in thrombogenicity, different
types of thrombophilia should be considered individually.
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7.2 to 2.6% per 100 person-years (hazard ratio [HR], 0.36; 95%
conﬁdence interval [CI], 0.19–0.67; p<0.001) with no signiﬁ-
cant increase in major bleeding (0.9 and 0.4 per 100 person-
years, respectively; HR, 2.53; 95% CI, 0.49–13.03; p¼0.25).14
However, when low-intensity warfarin (target INR 1.5–1.9)
was compared with conventional-intensity warfarin (target
INR 2.0–3.0) in a study of 738 patients with unprovoked VTE
whohadcompleted3months ofwarfarin therapy, the rateof
recurrent VTE was higher with the low-intensity warfarin
regimen than with the conventional-intensity regimen (1.9
and 0.7 per 100 person-years, respectively; HR, 2.8; 95% CI,
1.1–7.0; p¼0.03), whereas the rates of major bleeding were
similar (1.1and0.9per100person-years, respectively;HR,1.2;
95% CI, 0.4–3.0). Therefore, low-intensity warfarin is associat-
ed with a higher risk of recurrent VTE than conventional-
intensity therapy and does not decrease the risk of bleeding.15
Direct Oral Anticoagulants
VKAs require frequent coagulation monitoring and dose
adjustments to ensure that the INR remains within the
therapeutic range. Such monitoring is burdensome for
patients and health care providers.16 The development of
direct oral anticoagulants (DOACs) helped to overcome this
problem. These agents include dabigatran, which inhibits
thrombin, and apixaban, edoxaban, and rivaroxaban, which
inhibit factor Xa. When given in ﬁxed doses without moni-
toring, the DOACs have been shown to be at least as effective
as VKAs for the treatment of patients with acute VTE but are
associated with a 40% reduction in major bleeding.17–24
Because of these ﬁndings, current guidelines now give pref-
erence to the DOACs over VKAs for the treatment of VTE.3,6,7
The following phase III studies investigated the risk of
recurrent VTE with extended DOAC therapy: RE-SONATE,25
which compared dabigatran with placebo; RE-MEDY,25
which compared dabigatran with warfarin; AMPLIFY-
EXT,26which compared two doses of apixabanwith placebo;
EINSTEIN EXT,27which compared rivaroxabanwith placebo;
and EINSTEIN CHOICE,28 which compared two doses of
rivaroxaban with acetylsalicylic acid (ASA). Although not a
formal extension study, a post hoc analysis of patients who
received 3 to 12 months of anticoagulation in the Hokusai-
VTE trial, which compared edoxaban with warfarin, has also
been conducted due to the option of a ﬂexible therapy
duration of anticoagulation in that study.29 It is important
to note that there are several key differences between these
studies, including in enrolment numbers, endpoint deﬁni-
tions, study designs, inclusion/exclusion criteria, and patient
characteristics. For example, EINSTEIN EXT enrolled a higher
proportion of patients with active cancer than AMPLIFY-EXT
(4.5% vs. 1.7%, respectively), whereas AMPLIFY-EXT enrolled
more patients with unprovoked VTE than EINSTEIN EXT
(91.7% vs. 73.7%, respectively).26,27 Similarly, in the EINSTEIN
CHOICE (in which 41.3% of patients had unprovoked VTE)
and EINSTEIN EXT studies, the category deﬁnitions of
provoked and unprovoked VTE were not in line with com-
mon practice, but reﬂected more contemporary deﬁnitions
(e.g., VTE in patients with a family history of VTE or in those
with hereditary thrombophilia or obesity was classed as
“provoked by minor persistent risk factors,” despite these
events often beingdeﬁned as “unprovoked”).6,9,28Key details
for the trials with each of these agents are shown in►Table 2
and are described more fully below.
Dabigatran
The RE-SONATE and RE-MEDY studies of extended dabigatran
treatment inpatientswhohadcompleted3months of initial
anticoagulation therapy compared dabigatran with placebo
andwarfarin, respectively (with planned treatment periods of
6 to 18 months and 6 to 36 months, respectively). In RE-
SONATE, dabigatran signiﬁcantly reduced the rate of recurrent
or fatal VTE or unexplained death (unexplained death was an
additional endpoint in RE-SONATE only) versus placebo (0.4%
vs. 5.6%; HR, 0.08; 95% CI, 0.02–0.25; p<0.001), and in RE-
MEDY, dabigatran was noninferior to warfarin (1.8% vs. 1.3%;
HR, 1.44; 95% CI, 0.78–2.64; p<0.01).25 Rates of major bleed-
ing were not signiﬁcantly higher with dabigatran than with
warfarin or placebo, but the rate of the composite of major or
clinically relevant nonmajor (CRNM)bleedingwith dabigatran
wassigniﬁcantly lower than thatwithwarfarin (5.6%vs. 10.2%;
HR, 0.54; 95%CI, 0.41–0.71;p<0.001), but signiﬁcantly higher
than that with placebo (5.3% vs. 1.8%; HR, 2.92; 95% CI, 1.52–
5.60; p¼0.001).
Apixaban
AMPLIFY-EXT compared the treatment and thromboprophy-
lactic doses of apixaban (5 and 2.5mg twice daily, respec-
tively) with placebo in patients who had completed 6 to
12 months of anticoagulation therapy for their index VTE.26
Treatments were given for 12 months. Compared with
placebo, the rate of recurrent VTE and all-cause mortality
was signiﬁcantly lower with both apixaban regimens (11.6%
comparedwith 4.2 and3.8%with the 5 and 2.5mg twice daily
apixaban regimens, respectively; relative risk [RR], 0.36; 95%
CI, 0.25–0.53 and RR, 0.33; 95% CI, 0.22–0.48, respectively;
p<0.001 for both comparisons), without an increase in the
rates of major bleeding (0.5, 0.1, and 0.2%, respectively).
Rates of the composite endpoint of major or CRNM bleeding
with placebo, apixaban 5mg twice daily, and apixaban
2.5mg twice daily were 2.7, 4.3, and 3.2% (RR, 1.62; 95%
CI, 0.96–2.73, and RR, 1.20; 95%CI, 0.69–2.10), respectively.26
These results prompted a label update recommending the
2.5mg twice daily dose of apixaban for secondary prevention
in patients who had completed at least 6 months of anti-
coagulation treatment for their initial VTE event.30
Rivaroxaban
EINSTEIN EXT compared rivaroxaban 20mg once daily with
placebo for 6 or 12 months in patients who had completed 6
to 12 months of prior anticoagulation therapy.27 The rate of
recurrent VTEwas signiﬁcantly lower with rivaroxaban than
with placebo (1.3 and 7.1%, respectively; HR, 0.18; 95% CI,
0.09–0.39; p<0.001). The rate of major bleeding was not
signiﬁcantly increased (0.7 and 0% with rivaroxaban and
placebo, respectively; p¼0.11). However, the incidence of
CRNM bleeding was higher in the rivaroxaban group than in
those given placebo (5.4 and 1.2%, respectively); these were
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predominantly mucosal bleeding events and resumption of
anticoagulation occurred in most cases. The composite end-
point of CRNM and major bleeding was 6.0 and 1.2%, respec-
tively (HR, 5.19; 95% CI, 2.3–11.7; p<0.001).
EINSTEIN CHOICE compared the efﬁcacy and safety of the
treatment and thromboprophylactic doses of rivaroxaban (20
and 10mg once daily, respectively) versus ASA (100mg once
daily) for secondary prevention in 3,365 patients who had
completed 6 to 12 months of anticoagulation for their index
VTE, andwhowereatclinical equipoisewith regard to theneed
for continued anticoagulant treatment.28 Treatments were
given for up to 12months. ASAwas selected as the comparator
in the EINSTEIN CHOICE trial because it has been observed to
reduce the risk of VTE recurrence by approximately 32%
compared with placebo (5.1% vs. 7.5%; HR, 0.68; 95% CI,
0.51–0.90; p¼0.008) in patients for extended therapy who
had receivedat least3monthsofanticoagulation treatment for
unprovoked VTE.31 Both rivaroxaban doses signiﬁcantly re-
duced the risk of recurrent symptomatic fatal or nonfatal VTE
byapproximately 70% comparedwithASA. The incidence rates
were 1.5% with rivaroxaban 20mg once daily and 1.2% with
rivaroxaban 10mg once daily versus 4.4% with ASA (HR, 0.34;
95%CI, 0.20–0.59 andHR,0.26; 95%CI, 0.14–0.47, respectively;
p<0.001 for both comparisons). All groups showed similar
rates of major bleeding (0.5% with rivaroxaban 20mg once
daily, 0.4% with rivaroxaban 10mg once daily, and 0.3% with
ASA). The results supported regulatory approval of a rivarox-
aban label update, providing ﬂexibility to choose the reduced
rivaroxaban 10mg once daily dose for extended secondary
prevention of VTE for most patients.32,33 In addition, the
ﬁndings were broadly consistent across all patient subgroups
(e.g., provoked or unprovoked VTE, low-to-moderate creati-
nine clearance, high body weight, hereditary thrombophilia).
Further analyses of EINSTEIN CHOICE conﬁrmed the favorable
beneﬁt–risk proﬁle of rivaroxaban versus ASA. For every
10,000 patients treated for 1 year with rivaroxaban instead
ofASA, therewouldbe284(95%CI, 106–462) fewerepisodesof
symptomatic VTE and major bleeding (i.e., composite net
clinical beneﬁt outcomes) with the rivaroxaban 20mg dose
and 339 (95% CI, 165–512) fewer events with the rivaroxaban
10mg once daily dose.34
Abeneﬁt–risk analysis of rivaroxaban 20 and 10mg versus
ASA34 and a prespeciﬁed pooled analysis of data from the
EINSTEIN EXT and EINSTEIN CHOICE trials to assess the risk
of VTE according to baseline risk factor proﬁles9 are dis-
cussed further in subsequent sections of this review.
Edoxaban
The Hokusai-VTE trial compared edoxabanwith warfarin for
acute treatment of recurrent VTE, and all patients received at
least 3 months, and up to 12 months, of anticoagulation
treatment.35 Although this was not a formal extension study,
due to the ﬂexibility in duration of edoxaban treatment, a
prespeciﬁed post hoc analysis was conducted to evaluate
cumulative efﬁcacy and safety at 12months in those patients
who received 3 to 12months of treatment.29 The cumulative
incidence of symptomatic nonfatal and fatal VTE between 3
and 12 months was similar between the treatment groups
with incidence rates of recurrent VTE of 0.3% in the edox-
aban-treated group and 0.4% in the warfarin-treated group
(HR, 0.78; 95% CI, 0.36–1.72). The cumulative incidence of
major bleeding was lower with edoxaban thanwith warfarin
(0.3% vs. 0.7%; HR, 0.45; 95% CI, 0.22–0.92). The cumulative
incidence of major or CRNM bleeding events was 3.9% versus
4.1% (HR, 0.97; 95% CI, 0.77–1.22).
Guideline Recommendations Regarding the
Duration of Anticoagulant Treatment for
Venous Thromboembolism
Current guidelines recommend a minimum of a 3-month
course of anticoagulant treatment for all patients with
VTE.3,6,7 At 3 months, the decision to stop or to extend
anticoagulation therapy is based on the balance between
the risk of recurrent VTE if treatment is stopped and the risk
of bleeding if it is continued. Patient preference also factors
into the decision. Therefore, decisions about duration of
anticoagulation are both risk- and patient-focused.
A 3-month course of anticoagulation is adequate for
patients with VTE provoked by major transient risk factors
such as surgery or trauma because their risk of recurrence is
only approximately 1% at 1 year and 3% at 5 years.4 In contrast,
extended anticoagulation is recommended for patients with
unprovoked VTE and a lowormoderate risk of bleeding,3,6,7,36
because the risk of recurrence if anticoagulant therapy is
stopped is approximately 10% at 1 year and 30% at 5 years.37
In patients with a ﬁrst unprovoked VTE and a high risk of
bleeding, guidelines recommended stopping anticoagulation
therapy at 3 months.4,8 Extended anticoagulation is also
prescribed for most patients with VTE provoked by active
cancer because such patients have a risk of recurrence of at
least 15% at 1 year6; recurrence rates at 5 years have not been
determined because of the poor survival in cancer patients.6
The optimal duration of anticoagulation for patients with
VTE provoked by persistent or transient minor risk factors is
less clear, and guidelines do not distinguish between these
categories in their treatment recommendations. If VTE is
provoked by such minor factors as these, the risk of recur-
rence is likely to be higher than that in patients whose VTE
was triggered by major transient risk factors such as surgery
or trauma. Consequently, some patients with VTE provoked
by minor transient or minor persistent risk factors may be
candidates for extended anticoagulation therapy. A list of
minor persistent and transient risk factors and the associated
risks of VTE recurrence is shown in ►Table 3.
Broadening Anticoagulation Indications—
Potential New Subgroups for Extended
Venous Thromboembolism Treatment
Minor Transient Risk Factors
Minor transient risk factors for VTE include short-term
immobilization, leg injury with impaired mobility (e.g., a
plaster cast), long-distance travel (> 8hours), pregnancy and
puerperium, and use of estrogen therapies.9,11 In a meta-
analysis of data from prospective cohort and randomized
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studies, the rate of recurrence if anticoagulation therapywas
stopped after 3months of treatment was 4.2% per patient-
year in patients with VTE provoked by a nonsurgical tran-
sient risk factor (comparedwith 0.7 and 7.4% per-year in VTE
provoked by surgery and unprovoked VTE, respectively).11
Similarly, in the pooled analysis of EINSTEIN EXT and EIN-
STEIN CHOICE, the 1-year cumulative incidence of recurrent
VTE in patients whose VTE was provoked by a minor tran-
sient risk factor was 4.2% in those who received placebo and
4.2% in those who received ASA.9 For patients who had
received rivaroxaban, the 1-year cumulative incidence was
0.4%, suggesting that some patients with VTE provoked by
minor transient risk factors may beneﬁt from extended
anticoagulation (i.e., if the risk of recurrent VTE outweighs
the risk of bleeding). Although overall recurrence rates in
patients with VTE provoked by minor transient risk factors
were numerically lower than that in patients with unpro-
voked VTE, the difference was not statistically signiﬁcant
(HR, 0.68; 95% CI, 0.32–1.30). Therefore, additional studies
are needed to further delineate and conﬁrm the individual
factors that warrant such an approach.
Minor Persistent Risk Factors
Minor persistent risk factors for VTE recurrence include IBD,
lower extremity paralysis or paresis, CHF, chronic kidney
disease, BMI>30kg/m2, hereditary and acquired thrombo-
philia, a family history of VTE, residual vein occlusion (RVO),
and male gender.9,10,38,39 A list of minor persistent risk
factors and the associated risk of recurrence after stopping
anticoagulation therapy is shown in ►Table 3.
In a retrospective, population-based cohort study, the risk
of recurrent VTE over 6 to 7 years of follow-upwas evaluated
in patients who had received amean duration of 6months of
anticoagulation therapy for VTE. Minor persistent risk fac-
tors for VTE at baseline associated with an increased risk of
recurrence included IBD (HR, 2.37; 95% CI, 1.12–5.01), neu-
rological disease associatedwith extremity paresis (HR, 1.92;
95% CI, 1.33–2.77), and CHF (HR, 1.43; 95% CI, 1.04–1.97).
Chronic kidney disease at baselinewas a signiﬁcant predictor
of recurrence in a subset of patients with “probably/deﬁnite”
(as opposed to “possible”) VTE recurrence (HR, 2.83; 95% CI,
1.05–7.62). A BMI of  30kg/m2 was not associated with an
increased risk of recurrence in this study. However, in a
cohort study of 1,107 patients who had been treated with
anticoagulation therapy for  3 months, the rate of recur-
rence after stopping anticoagulation therapywas signiﬁcant-
ly higher in patients classiﬁed as obese (BMI  30kg/m2)
compared with patients with a BMI of<25 kg/m2 (adjusted
HR, 1.6; 95% CI, 1.1–2.4; p¼0.02).40
The risk of recurrence in patients with IBD was further
evaluated in a prospective study of patients with a ﬁrst
unprovoked VTE. The study included 2,811 patients with IBD
(diagnosed in accordance with the European Crohn’s and
Colitis Organization guidelines) and 1,255 patients without
IBD. Patients with IBD had a signiﬁcantly higher rate of
recurrent VTE 5 years after stopping anticoagulant therapy
than those without (33.4% vs. 21.7%, respectively; p¼0.01).41
After adjustment for possible confounders, IBD was demon-
strated to be an independent risk factor for recurrent VTE (HR,
2.5; 95% CI, 1.4–4.2; p¼0.001). Half of the IBD patients had
active disease at the time of recurrent VTE. The impact of
decreased renal function on the risk of recurrencewas further
evaluated in an observational study that prospectively fol-
lowed a subgroup of 260 patients with VTE who had stopped
anticoagulation therapy and had not yet had a recurrence.
Compared with patients with normal renal function, the risk
was increased in patients with chronic kidney disease (esti-
mated glomerular ﬁltration rate [eGFR]<60mL/min/1.73m2;
HR, 5.32; 95% CI, 1.49–18.95; p¼0.010) or more moderate
renal disease (eGFR 60–90mL/min/1.73m2; HR, 2.84; 95% CI,
1.13–7.11; p¼0.025).42
Regarding hereditary thrombophilia, the risk of recurrent
VTE is slightly higher in those heterozygous for the factor V
Leiden mutation (HR, 1.5; 95% CI, 1.1–1.9) or the prothrom-
bin gene mutation (HR, 1.4; 95% CI, 1.0–1.8) than in those
without thesemutations.43After adjustment for age, sex, and
the circumstances of the initial venous thromboembolic
event, the risk of recurrence after stopping anticoagulant
therapy was higher in patients with antithrombin deﬁciency
than in patients without (HR, 1.9; 95% CI, 1.0–3.9).44 In the
same study, there was a marginal increase in the risk of
recurrence in patients with protein C or protein S deﬁciency
comparedwith patientswithout thrombophilia (HR, 1.4; 95%
CI, 0.9–2.2).44 In patients with a family history of VTE, a
Swedish registry demonstrated that the risk of hospitaliza-
tion for recurrent VTE was slightly elevated in those with a
parental (HR, 1.20; 95% CI, 1.10–1.32) or sibling (HR, 1.30;
95% CI, 1.14–1.49) history of VTE versus those with no such
history.45 In those where both parents had experienced VTE,
the risk was further increased versus those with no parental
history of VTE (HR, 1.92; 95% CI, 1.44–2.58).45 However,
other studies have been unable to demonstrate a connection
between recurrence risk and family history of VTE.46
The pooled analysis of EINSTEIN EXT and EINSTEIN
CHOICE evaluated the risk of VTE recurrence in patients
with the minor persistent risk factors outlined above. The
1-year cumulative incidence of recurrent VTE in these
patients was 10.7% in patients who had received placebo,
4.5% in thosewho received ASA, and 2.4% in patientswho had
received rivaroxaban. The overall rate of recurrence in
patients with minor persistent risk factors was statistically
similar to that observedwith unprovoked VTE (HR, 0.68; 95%
CI, 0.32–1.30).9 As per discussions regardingminor transient
risk factors, results from this analysis suggest that some
patients with minor persistent risk factors may beneﬁt from
extended anticoagulation therapy.
Additional persistent risk factors to consider include RVO
and male gender. The prognostic value of RVO is difﬁcult to
assess because of differences in RVO assessment across
studies.47 A meta-analysis of 2,527 patients from 10 studies
investigating the utility of RVO for predicting the risk of
recurrence after at least 3 months of anticoagulant therapy
for unprovoked VTE found a small association that appeared
to be dependent on the time of RVO assessment after the
index venous thromboembolic event (HR, 1.32; 95% CI, 1.06–
1.65).38 RVO detected at 3 months was associated with a
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higher risk of recurrent VTE (HR, 2.17; 95% CI, 1.11–4.25);
however, this association was no longer observed after
6 months (HR, 1.19; 95% CI, 0.87–1.61).38 In another meta-
analysis, RVO was not associated with an increased risk of
recurrent VTE (odds ratio [OR], 1.24; 95% CI, 0.9–1.7) in
patients with unprovoked DVTwho stopped oral anticoagu-
lation therapy at the time of assessment for RVO. However,
RVO was signiﬁcantly associated with recurrent VTE in
patients with any (unprovoked or provoked) DVT (OR, 1.5;
95% CI, 1.1–2.0).48 Finally, in a patient-level meta-analysis of
2,554 patients, a twofold higher risk for VTE recurrence was
observed in male patients with unprovoked VTE than in
female patients (HR, 2.2; 95% CI, 1.7–2.8).39 This increase in
risk remained after exclusion of women with hormone-
associated VTE (HR, 1.8; 95% CI, 1.4–2.5), but was not
observed in patients with provoked VTE (HR, 1.2; 95% CI,
0.6–2.4).39 Therefore, the value of RVO as a predictor of
recurrence remains uncertain, but men with unprovoked
VTE are at higher risk of recurrence than women.
Optimal Dose of Anticoagulant for Extended
Venous Thromboembolism Treatment
Thebeneﬁt–riskproﬁleof reducedversus fulldosesofapixaban
or rivaroxaban was examined in a recent meta-analysis that
included the AMPLIFY-EXT and EINSTEIN CHOICE trials. Com-
pared with full-dose apixaban or rivaroxaban, the reduced-
dose regimens were associated with a trend for less clinically
relevant bleeding (2.3% vs. 3.7%; RR, 0.74; 95% CI, 0.52–1.05;
p¼0.09) andnosigniﬁcant increase in the riskof recurrentVTE
(1.6% vs. 1.4%; RR, 1.12; 95% CI, 0.67–1.87; p¼0.67).49
Individual beneﬁt–risk analyses for AMPLIFY-EXT and
EINSTEIN CHOICE have also been published. In an analysis
of data from AMPLIFY-EXT, it was shown that during the
1-year study period 14 patients would need to be treated
with apixaban to prevent a recurrent fatal or nonfatal venous
thromboembolic event, whereas 200 patients would need to
receive apixaban for a major bleeding or CRNM bleeding
event to occur.26 In an analysis of data from EINSTEIN
CHOICE, it was revealed that for every 10,000 patients
with VTE treated for 1 year with rivaroxaban 20 or 10mg
once daily instead of ASA, 312 (95% CI, 144–479) and 341
(95% CI, 175–507) fewer recurrent venous thromboembolic
eventswould result, respectively (number needed to treat 33
and 30 patients, respectively).34 In terms of safety, for every
10,000 patients who received rivaroxaban 20 or 10mg once
daily for 1 year instead of ASA therewould be 28 (95% CI,43
to 99) and 0 (95% CI, 60 to 59) more major bleeding events,
respectively (number needed to harm 356 and 0, respective-
ly). With rivaroxaban 10mg once daily it would take nearly
60,000 patients to be treated to cause an additional bleeding
event. Therefore, the reduced-dose regimens of apixaban or
rivaroxaban appear to provide greater safety than full doses,
without loss of efﬁcacy.
With regard to the impact of minor persistent and tran-
sient risk factors, the EINSTEIN CHOICE study analyzed
beneﬁt–risk data in more detail in 3,365 patients with VTE
treated with rivaroxaban (20 or 10mg) or ASA.34 Results of
this analysis are shown in ►Table 4, and translate into an
annual net clinical beneﬁt that favors the use of rivaroxaban
10mg over the use of rivaroxaban 20mg for continued
therapy in patients with clinical equipoise for extended
therapy. The number needed to treat to prevent one addi-
tional event with rivaroxaban 20mg versus 10mg being 33
and 24 patients (unprovoked VTE), 49 and 42 patients (VTE
byminor persistent risk factors), and 35 and 29 patients (VTE
byminor transient risk factors), respectively. For the remain-
ing DOACs, no such subanalysis regarding minor VTE risk
factors has been reported.
Selecting the Right Dose for the Right
Patient: Clinical and Practical
Considerations on Extended Venous
Thromboembolism Treatment Dosing
How should physicians select the best dose for each patient?
All patients with VTE require at least 3 months of anticoagu-
lant therapy. The decision to extend anticoagulation therapy
beyond 3 months depends on the balance between the risk of
recurrence if anticoagulation therapy is stopped and the riskof
bleeding if it is continued. For extended therapy,most patients
treated with apixaban or rivaroxaban can be switched to the
low-dose regimens. We advise delaying this switch until
patients have completed at least 6 months of treatment
with the full-dose regimen because earlier initiation of the
lower-dose regimens has not been evaluated. Patients who
should remain on the high-dose regimens include those who
havehad a recurrence on a reduced-dose regimen and those at
high risk of recurrence such as patients with active cancer or
those with thrombophilic disorders, because such patients
Table 4 Numbers of fewer than expected recurrent venous thromboembolic events and additional expected major bleeding
events with rivaroxaban 20 and 10mg compared with ASA in the ENSTEIN CHOICE trial34
n (95% CI) Unprovoked VTE Minor persistent Minor transient
Rivaroxaban
dose
20 mg 10 mg 20 mg 10 mg 20 mg 10 mg
Recurrent
VTE
386
(646 to 125)
419
(672 to 167)
226
(503 to 51)
243
(533 to 46)
323
(775 to 130)
419
(831 to 7)
Major
bleeding
75
(29 to 179)
21
(52 to 93)
21
(20 to 63)
0 150
(308 to 609)
72
(299 to 443)
Abbreviations: ASA, acetylsalicylic acid; CI, conﬁdence interval; VTE, venous thromboembolism.
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were underrepresented in the extended treatment trials.
Patient preference also needs to be considered. For example,
selection of a reduced-dose regimenmay provide reassurance
for patients with a history of bleeding, or for those participat-
ing in contact sports or those who work under hazardous
conditions. In contrast, continuation of the full-dose regimen
may provide reassurance for the VTE patient with life-threat-
ening PE or a family history of fatal PE. Patients also have the
option to re-escalate to a higher dosage if required. Therefore,
with the choice of two-dose regimens, selection can be
personalized based on individual beneﬁt–risk considerations.
An overview of the dosing guidance for the four DOACs for
extended treatment from their respective product labels
DOACs is provided in ►Fig. 1.
The optimal duration of anticoagulation in patients with
VTE provoked by minor transient or persistent risk factors is
uncertain, but some of these patients are likely to need
extended treatment similar to those with unprovoked VTE.
Additional studies areneededto identify thehighest riskminor
transient or persistent risk factors. Regardless, regular assess-
ment of risk factors for VTE and bleeding and regular con-
versationswith the patienton their preferences regardingdose
and duration of therapy are key to best outcomes for patients.
A furtherpoint tonote is that the2016 International Society
on Thrombosis and Haemostasis Scientiﬁc and Standardiza-
tion Committee guidance on the use of DOACs in obese
patients suggests that DOACs should not be used in patients
with a BMI of>40kg/m2 and weight>120kg for VTE treat-
ment because of a possible risk of underdosing and a lack of
clinical evidence for DOAC use at the extremes of body
weight.50However, theEuropeanandNorthAmericanproduct
labels for apixaban, dabigatran, edoxaban, and rivaroxaban do
not restrict useofDOACs forhighweight or BMI.30,32,51–55 This
is based on the fact that body weight had little inﬂuence on
plasma concentrations of DOACs inpharmacokinetic/pharma-
codynamic studies. In a recently published analysis of 3,458
patients taking a DOAC prior to admission to a single health
system between February 2013 and August 2016, obesity did
not signiﬁcantly correlate with thrombotic or overt bleeding
complications.56 However, further research is still needed,
especially considering that patients who are obese often
have additional comorbidities, which may affect the risk of
thrombosis and/or bleeding. In fact, all relevant factors should
be considered when choosing the optimal dose of DOAC
therapy for long-term and extended therapy.
Conclusion and Future Directions
Extended treatment studies and subanalyses of phase III
studies of patients receiving longer-duration therapy are
now available for the four DOACs across a broad range of
patients. The option for reduced doses of rivaroxaban and
apixaban for extended therapy offers VTE prophylaxis with
little increase in bleeding risk, which helps to tailor treat-
ment to the needs of speciﬁc patients. The availability of two
rivaroxaban and apixaban dosing regimens coupledwith the
option for dose re-escalation from the low dose to the full
dose gives ﬂexibility to meet patient preferences and physi-
cian recommendations. Analysis of more granular deﬁni-
tions for risk factor groupings than those used in the
traditional schema of provoked versus unprovoked VTE has
also yielded vital information on the most appropriate
strategies for the treatment of patients with speciﬁc risk
factors. Such analyses highlight the fact that extended
Fig. 1 Dosing schedules for the four direct oral anticoagulants for initial, long-term and extended VTE treatment. 2.5mg bid extended dose
initiated following completion of 6 months of treatment with apixaban 5mg bid or with another anticoagulant; #Dose reduction recommended
in patients aged  80 years old or who receive concomitant verapamil; dose reduction should be considered in patients aged 75–80 years old,
with moderate renal impairment (CrCl 30–50mL/min), gastritis, esophagitis or gastroesophageal reﬂux, or other patients at an increased risk of
bleeding; ‡Dose reduction recommended in patients with moderate renal impairment (CrCl 15–50mL/min), low body weight ( 60 kg), or who
receive concomitant P-glycoprotein inhibitors; §In patients with CrCl 15–49mL/min if the patient’s assessed risk of bleeding outweighs that of
VTE; ¶10mg od extended dose initiated following completion of at least 6 months’ therapy for DVTor PE; Dose increase should be considered in
patients with a high risk of recurrent DVT or PE, such as those with complicated comorbidities or those who have developed recurrent VTE on
extended prevention with rivaroxaban 10mg od. bid, twice daily; CrCl, creatinine clearance; DVT, deep vein thrombosis; od, once daily; PE,
pulmonary embolism; VTE, venous thromboembolism.
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anticoagulation treatment may beneﬁt those with VTE pro-
voked by minor transient and persistent environmental and
nonenvironmental risk factors who commonly receive
shorter-duration therapy. The ﬁndings described in this
review are likely to inﬂuence future updates to clinical
guidelines for long-term VTE treatment. Finally, for some
patients, there still exists a degree of uncertainty as to the
optimal approach for extended therapy; therefore, future
studies will be important to reﬁne the best management
strategies for such patients.
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